aflibercept   Click here for help

GtoPdb Ligand ID: 6786

Synonyms: AVE0005 | Eylea® | VEGF Trap | Zaltrap® | ziv-aflibercept
Approved drug
aflibercept is an approved drug (FDA (2011), EMA (2012))
Compound class: Antibody
Comment: Alfibercept is a fusion protein combining the Fc portion of human IgG with the ligand binding domains of the VEGRF1 and VEGRF2 receptors.

Biosimilars:
Patent protection for originator alfibercept is expected to expire earliest in Japan and China (2022), then in US (2023, if Regeneron's extended patent claims are accepted) and the EU (2025), and biosimilar development is underway [3]. Examples include Momenta Pharmaceuticals/Mylan's M710, Alteogen's ALT-L9 (a heat stabilised formulation with a predicted longer shelf-life than Eylea; NCT04058535), and Formycon/Santo Holdings' FYB203.
References
1. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M. (2014)
Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.
Ophthalmology, 121 (1): 188-92. [PMID:24144450]
2. Chu QS. (2009)
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
Expert Opin Biol Ther, 9 (2): 263-71. [PMID:19236257]
3. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. (2018)
Biosimilars in ophthalmology: "Is there a big change on the horizon?".
Clin Ophthalmol, 12: 2137-2143. [PMID:30498330]
4. Tang PA, Moore MJ. (2013)
Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations.
Therap Adv Gastroenterol, 6 (6): 459-73. [PMID:24179482]